Aubrey Dan, a Director, acquired 500,000 Common Shares on an indirect ownership basis for registered holder Dancap Private Equity Inc. at a price of $1.000 through a private transaction on November 30th, 2017. The insider also acquired 250,000 Warrants with an exercise price of $1.200 for 3 years. This represents a $500,000 net investment into the company's shares and an account share holdings change of greater than 100%.
On the same terms, Kathryn Vanessa Austin Grant, also a Director, acquired 10,000 Common Shares and 5,000 Warrants on a direct ownership basis. This represents a $10,000 investment into the company's shares and an account share holdings change of 30.0%.
Avivagen is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
Avivagen Inc is a Canada-based life sciences company. It develops products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal's own health defenses. Its segments include products based on fully-oxidized beta-carotene (OxC-beta) technology and chemistry product sales. Its OxC-beta technology is in trials as a non-antibiotic feed additive. Its products include OxC-beta Livestock, Vivamune Health Chews and Oximunol Chewable Tablets. Its Vivamune Health Chews are supplements that are suitable for pets in all life stages and can be given to dogs and cats as young as over five weeks of age. The Oximunol Chewable Tablets are available in bottles through veterinarians across the United States. The OxC-beta Livestock is available for sale in Taiwan, Thailand and the Philippines. Its customers include government agencies, global health organizations, livestock producers and end market food companies.
No Comments